Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10942803 | 0.98 | L3MBTL1 (0.58) | TSHRL3MBTL1PAOXKMT2AMEN1 | |
| SCHEMBL25622494 | 0.98 | L3MBTL1 (0.58) | TSHRL3MBTL1PAOXKMT2AMEN1 | |
| SCHEMBL7141667 | 0.94 | TSHR (0.58) | TSHRL3MBTL1PAOXKMT2AMEN1 | |
| SCHEMBL24163781 | 0.87 | L3MBTL1 (0.53) | TSHRL3MBTL1PAOXKMT2AMEN1 | |
| SCHEMBL17451524 | 0.87 | TSHR (0.61) | TSHRL3MBTL1KMT2AMEN1KDM5A | |
| SCHEMBL26735008 | 0.86 | L3MBTL1 (0.51) | TSHRL3MBTL1PAOXKMT2AMEN1 | |
| SCHEMBL8747893 | 0.85 | KMT2A (0.58) | TSHRL3MBTL1PAOXKMT2AMEN1 | |
| SCHEMBL11800393 | 0.84 | KDM5A (0.54) | TSHRL3MBTL1KDM5AALDH1A1LMNA | |
| Hexadecanoic Acid Methyl Ester SCHEMBL28398014 | 0.84 | KDM5A (0.58) | TSHRL3MBTL1KDM5AALDH1A1LMNA | |
| SCHEMBL13903730 | 0.84 | KDM5A (0.58) | TSHRL3MBTL1KDM5AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023250375-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | ORNA THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-4289951-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023056033-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | ORNA THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2021030701-A1 | IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2021-02-18 | — | — | WO | disclosed |
| WO-2018081480-A1 | LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2018-05-03 | — | — | WO | disclosed |
| WO-2017117528-A1 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2017-07-06 | — | — | WO | disclosed |
| US-20160139136-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160139136-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS | FUT5, FUT6, CSGALNACT1 | TSHR 2074/4885L3MBTL1 2584/4885PAOX 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.